Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 8/20 | 0.62 |
| ▸ | DBF4 | Q9UBU7 | 8/20 | 0.62 |
| ▸ | TRPM8 | Q7Z2W7 | 6/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12186978 | 0.88 | CDC7 (0.64) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL8867093 | 0.85 | CDC7 (0.62) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL19523297 | 0.85 | CDC7 (0.62) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL15383553 | 0.84 | ALDH1A1 (0.62) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL454793 | 0.83 | CDC7 (0.59) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL29627451 | 0.83 | CDC7 (0.59) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL4464882 | 0.83 | CDC7 (0.73) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL19523327 | 0.82 | MAPT (0.58) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL30804867 | 0.82 | CDC7 (0.58) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL469731 | 0.82 | CDC7 (0.58) | CDC7DBF4TRPM8MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172571-A1 | PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE | NATCO PHARMA LIMITED (IN) | 2013-07-04 | — | — | US | claimed |
| WO-2012032528-A2 | IMPROVED PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE | NATCO PHARMA LIMITED (IN) | 2012-03-15 | — | — | WO | claimed |
| WO-2014121695-A1 | NOVEL XANTHINE OXIDASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | 镇江新元素医药科技有限公司 (CN) | 2014-08-14 | — | — | WO | disclosed |
| US-20130172571-A1 | PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE | NATCO PHARMA LIMITED (IN) | 2013-07-04 | — | — | US | disclosed |
| US-20130172571-A1 | PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE | NATCO PHARMA LIMITED (IN) | 2013-07-04 | — | — | US | disclosed |
| US-20130172571-A1 | PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE | NATCO PHARMA LIMITED (IN) | 2013-07-04 | — | — | US | disclosed |
| WO-2012032528-A2 | IMPROVED PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE | NATCO PHARMA LIMITED (IN) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012032528-A2 | IMPROVED PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE | NATCO PHARMA LIMITED (IN) | 2012-03-15 | — | — | WO | disclosed |
| US-5614520-A | 2-arylthiazole derivatives and pharmaceutical composition thereof | TEIJIN LIMITED (JP) | 1997-03-25 | — | — | US | disclosed |
| EP-0513379-B1 | 2-ARYLTHIAZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TEIJIN LTD (JP) | 1996-09-11 | — | — | EP | disclosed |
| EP-0513379-A1 | 2-ARYLTHIAZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TEIJIN LIMITED (JP) | 1992-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172571-A1 | PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE | FIP1L1, UMPS, UBXN4 | CDC7 4019/4885DBF4 2965/4885TRPM8 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.